Paeds Vivas · allergy-and-immunology
Anaphylaxis prevention, action plans and autoinjectors — branching viva
Branching structured-oral viva on the community anaphylaxis prevention package: the pharmacology of adrenaline and why the intramuscular outer-thigh route, the weight-band transitions for autoinjector dosing, the biphasic reaction and the mandatory observation window, school readiness and the education ladder, and the fatal-risk triad of adolescence with peanut or tree-nut allergy and uncontrolled asthma — covering adrenaline-first reasoning, the green-to-red escalation, and adolescent transition.
On this page
Study tools
Target exams
Opening question
Examiner: Take me through this boy. What is your frame for the prevention prescription, and what are you going to write today? [1]
Candidate: My frame is that a child at risk of anaphylaxis is kept alive by a package, not by a single intervention, and the visit today is about building that package so it travels with him. He has had a confirmed anaphylactic reaction to peanut, so he is at risk of recurrence, and my job is to make sure that the next reaction is survivable wherever it happens. The package has six components: confirmed trigger avoidance, the green and red ASCIA action plans, the weight-appropriate adrenaline autoinjector, two devices and a trainer, rehearsed education of every carer, and optimised asthma control with a review date. I am going to write all six today, because any one of them alone is insufficient. [10]
Examiner: Why two plans rather than one? [10]
Candidate: Because the decision the plan exists to make is when to cross from a mild reaction to anaphylaxis, and the colour coding removes that deliberation at the moment of crisis. The green plan covers mild-to-moderate reactions — skin and mild gut symptoms — where the carer gives an antihistamine and watches closely for escalation. The red plan triggers adrenaline the moment anaphylaxis is recognised: any airway or breathing problem, collapse or pallor, or a rapid reaction involving skin plus another body system. The carer does not diagnose; they read the colour, and that single design feature is what makes the plan usable under stress by a non-clinician. [10]
References9ShowHide
- [1]Sampson HA; Muñoz-Furlong A; Campbell RL; et al Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol, 2006.PMID 16461139
- [2]Brown SG Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol, 2004.PMID 15316518
- [3]Simons FE; Ardusso LR; Bilò MB; et al; World Allergy Organization 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol, 2012.PMID 22744267
- [4]Shaker MS; Wallace DV; Golden DBK; et al Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol, 2020.PMID 32001253
- [9]Simons FE First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol, 2004.PMID 15131564
- [10]Sicherer SH; Simons FER; SECTION ON ALLERGY AND IMMUNOLOGY Epinephrine for First-aid Management of Anaphylaxis. Pediatrics, 2017.PMID 28193791
- [11]Turner PJ; Jerschow E; Umasunthar T; Lin R; Campbell DE; Boyle RJ Fatal Anaphylaxis: Mortality Rate and Risk Factors. J Allergy Clin Immunol Pract, 2017.PMID 28888247
- [12]Lee S; Bellolio MF; Hess EP; et al Time of Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic Review and Meta-analysis. J Allergy Clin Immunol Pract, 2015.PMID 25680923
- [13]Mehr S; Liew WK; Tey D; Tang ML Clinical predictors for biphasic reactions in children presenting with anaphylaxis. Clin Exp Allergy, 2009.PMID 19486033